Sr. Director, US Team Lead, LORBRENA​/BRAF Lung

Role Summary

Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting‑edge science into market‑shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI‑enabled infrastructure and the authority to accelerate medicines from discovery to delivery.

Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you—across teams, roles, and the Pfizer enterprise.

The US Precision Medicine Thoracic Franchise is entering its most consequential – and most complex – growth chapter. Our in‑line thoracic portfolio spans two biomarker‑defined populations: LORBRENA (lorlatinib) for adults with ALK‑positive metastatic non‑small cell lung cancer (NSCLC), and the BRAFTOVI + MEKTOVI (encorafenib + binimetinib) regimen for BRAF V600E‑mutant metastatic NSCLC. Both sit inside a molecularly driven treatment landscape where the right patient is identified by a biomarker signature.

Winning here means mastering precision targeting: reaching narrow, high‑value, genomically defined patient populations through the exact clinicians who test for and treat them.

This is a people‑management leadership role that demands a strong enterprise leader — one fluent in both commercial strategy and AI‑enabled execution, and able to think and operate at the enterprise level. The colleague who leads this team will set a multi‑year strategic vision, make thoughtful trade‑off and resource‑prioritization decisions across two brands, and influence senior leadership across the wider organization.

They will operate in an AI‑enabled commercial environment where machine‑learning‑driven customer identification, next‑best‑action engines, and predictive analytics reshape how, when, and to whom we deliver our message. This person will be required to leverage deep US commercial marketing experience and precision‑targeting expertise to lead a highly talented team, connect targeted precision engagement activity directly to outcomes, and elevate what we are able to say — and prove — to our customers in a data‑rich, AI‑enabled world.

• Directly own the design and execution of an AI‑enabled marketing strategy — leveraging machine learning, predictive analytics and next‑best‑action engines to identify, prioritize and engage the right precision‑medicine customers at the right moment.
• Lead the complexity of precision targeting across two biomarker‑defined NSCLC populations (ALK+ and BRAF V600E‑mutant) aligning brand strategy, diagnostic/testing pathways and HCP engagement so the right patients are identified and reached.
• Set a multi‑year strategic vision for the lung portfolio — anticipating shifts in the ALK+ and BRAF V600E‑mutant competitive landscape, evolving standards of care, and biomarker‑testing dynamics, and shaping brand strategy today to protect and grow the franchise over a 3–5‑year horizon.
• Partner cross‑functionally with the BRAFTOVI + MEKTOVI brand team to drive the BRAF V600E‑mutant NSCLC (lung) indication — coordinating lung‑specific strategy, promotional review, biomarker‑testing initiatives and field execution.
• Connect the patient journey — build the operating model, metrics and feedback loops that connect field sales and marketing execution directly to patients and hold both accountable to shared commercial outcomes.
• Strategize proactively with the Market Access…